Australia's CurveBeam AI shares double in value on FDA nod for CT scan tech
15/09/2026 03:18
BUZZ-Australia's CurveBeam AI shares double in value on FDA nod for CT scan tech ** Shares of Australia's Curvebeam AI CVB.AX double in value to A$0.040, post record intraday pct gain
** Stock hits its highest level since June 17
** AI diagnostics firm secures U.S. FDA clearance for CT scan bone density technology
** Co says approval allows future SaaS revenue opportunities across CT imaging portfolio
** Co plans to seek FDA clearance to expand technology to its propreitary CT imaging platform HiRise, potentially broadening its commercial market
** YTD, stock down 63.5%, including the day's moves
(Reporting by Paridhi Minda in Bengaluru)
Recent news on Curvebeam AI
See all newsAustralia's CurveBeam rises on Chinese approval of medical imaging device
Brief: Curvebeam AI Seeks Trading Halt
Australia's CurveBeam AI shares double in value on FDA nod for CT scan tech
Australia's CurveBeam AI on track for best day in 3 weeks on premium placement
Brief: Curvebeam AI Secures A$5 Million Placement, A$1 Million Share Purchase Plan